Current US payer's perceptions on value-based pricing for pharmaceuticals

Whitepaper

Current US payer's perceptions on value-based pricing for pharmaceuticals

Hero
 

Examining Payer Reliance on ICER Assessments and Perceptions on Value-Based Pricing

 

A recent influx of high-priced drugs has led to a discussion around whether prescription drug prices should reflect, more accurately, the level of improvement in patient outcomes. To address this, the Institute for Clinical and Economic Review (ICER) launched an international collaboration to develop new methods to guide value-based pricing.

This initiative prompted ICON to conduct research on ICER assessments and perceptions on value-based pricing over the past year. Read our whitepaper, "Payer Reliance on ICER Assessments and Perceptions on Value Based Pricing" to learn more.

 
DOWNLOAD THE WHITEPAPER
 
 
     
 
ICONplc.com
 

This email was sent on behalf of the sponsor by HealthEconomics.Com, 1327 Walnut, Jacksonville, FL, 32206.
If you don't wish to receive further Industry Leaders News Updates from us, you may immediately unsubscribe from this list here, or send your request in writing to the address above.
Read more about our privacy policy here. You may also request a copy in writing using the address above.

To ensure you continue to receive emails from HealthEconomics.Com, please click here.